ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1716 • ACR Convergence 2021

    Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center

    Shruti Chandramouli1, Carolina Alvarez2, R. Gina Silverstein3 and Saira Sheikh4, 1Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Department of Obstetrics & Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 4University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, who have an increased risk of pregnancy complications such as preterm labor and preeclampsia,…
  • Abstract Number: 1715 • ACR Convergence 2021

    Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians

    Daiva Mitchell1, Leslie Lesoon1, Cuoghi Edens2, Traci Kazmerski3, Olivia Stransky4, Megan Clowse5, Sonya Borrero4 and Mehret Birru Talabi4, 1UPMC, Pittsburgh, PA, 2University of Chicago, Chicago, IL, 3Children's Hospital of Pittsburgh, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA, 5Duke University, Chapel Hill, NC

    Background/Purpose: While rheumatologists in several descriptive studies have acknowledged the importance of family planning in their care of women with rheumatic diseases, they have also…
  • Abstract Number: 1706 • ACR Convergence 2021

    Twenty-four-week Follow-up of a Randomized Controlled First-in-Human Trial of the Safety and Efficacy of Neurostimulation with a Miniaturized Vagus Nerve Stimulation Device in Patients with Multidrug-Refractory Rheumatoid Arthritis

    Norman Gaylis1, Mark Genovese2, David Sikes3, Alan Kivitz4, Diane Horowitz5, Charles Peterfy6, Yaakov Levine7 and David Chernoff8, 1Arthritis and Rheumatic Disease Specialties, Aventura, FL, 2Stanford University, Sunnyvale, CA, 3Florida Medical Clinic, Wesley Chapel, FL, 4Altoona Center for Clinical Research, Duncansville, PA, 5Northwell Health, Jericho, NY, 6Spire Sciences, Inc., Boca Raton, FL, 7SetPoint Medical, Manhassest, NY, 8SetPoint Medical, Sausalito, CA

    Background/Purpose: Vagus nerve stimulation (VNS) activates innate neuroimmune reflexes that have been shown to reduce pro-inflammatory cytokines and clinical disease activity in subjects with rheumatoid…
  • Abstract Number: 1710 • ACR Convergence 2021

    Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial

    Daniel Aletaha1, Rene Westhovens2, Tatsuya Atsumi3, YingMeei Tan4, Alena Pechonkina5, Qi Gong5, Vijay Rajendran6, Sander Strengholt7 and Gerd Burmester8, 1Medical University Vienna, Vienna, Austria, 2University Hospitals KU Leuven, Maaseik, Belgium, 3Hokkaido University, Sapporo, Japan, 4Gilead Sciences, Inc, San Diego, CA, 5Gilead Sciences, Inc., Foster City, CA, 6Galapagos NV, Mechelen, Belgium, 7Galapagos, BV, New York, NY, 8Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
  • Abstract Number: 1723 • ACR Convergence 2021

    Factors Associated with Postpartum Flare in Women with Lupus

    Anitha Ramu1, Maedeh Veyseh1, Brianna Lally2, Shudan Wang3 and Anna Broder4, 1Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 4Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

    Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…
  • Abstract Number: 1718 • ACR Convergence 2021

    Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide

    Jun Chu1, Alice Fike2, Michael Davis3, Zerai Manna4, Komal Ejaz5, Yenealem Temesgen-Oyelakin6, Elaine Poncio7, Isabel Ochoa7, Alan Decherney4 and Sarfaraz Hasni4, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3NIAMS, Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5Sheikh Zayed Medical College, Scranton, PA, 6National Institutes of Health (NIH), Bethesda, MD, 7NIH/NIAMS, Bethesda, MD

    Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…
  • Abstract Number: 1714 • ACR Convergence 2021

    Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases

    Olivia Stransky1, Nicole Hunt2, John Richards3 and Mehret Birru Talabi1, 1University of Pittsburgh, Pittsburgh, PA, 2UPMC, Pittsburgh, PA, 3Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA

    Background/Purpose: Few studies have comprehensively evaluated the information needs and priorities that men with rheumatic diseases have about their sexual and reproductive health (SRH). This…
  • Abstract Number: 1678 • ACR Convergence 2021

    Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

    Maarten Boers1, Linda Hartman1, Daniela Opris-Belinski2, Reinhard Bos3, Marc Kok4, Jose Pereira da Silva5, Ed Griep6, Ruth Klaasen7, Cornelia F. Allaart8, Paul Baudoin9, Hennie Raterman10, Zoltan Szekanecz11, Frank Buttgereit12, Pavol Masaryk13, L. Thomas Klausch1, Sabrina Paolino14, Annemarie Schilder3, Willem Lems15 and Maurizio Cutolo14, 1Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 2Carol Davila University, Bucharest, Romania, 3Medical Center Leeuwarden, Leeuwarden, Netherlands, 4Maasstad Hospital, Rotterdam, Netherlands, 5University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, 6Antonius Hospital, Sneek, Netherlands, 7Meander Medical Center, Amersfoort, Netherlands, 8Leiden University Medical Center, Leiden, Netherlands, 9Reumazorg Flevoland, Emmeloord, Netherlands, 10Northwest Clinics, Alkmaar, Netherlands, 11Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 12Charité – Universitätsmedizin Berlin, Berlin, Germany, 13National Institute for the Rheumatic Diseases, Bratislava, Slovakia, 14Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, 15VUmc, Amsterdam, Netherlands

    Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
  • Abstract Number: 1700 • ACR Convergence 2021

    Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib

    Céleste van der Togt1, Lise Verhoef2, Nathan den Broeder3, Rob ter Heine3, Bart van den Bemt4 and Alfons den Broeder5, 1Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, 4Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, 5Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
  • Abstract Number: 1728 • ACR Convergence 2021

    Takayasu’s Arteritis and Pregnancy: A Meta-analysis

    Aine Gorman1, Leah Rooney2, Matthew Turk1, Louise Moore3, Jared Bierbrier4, Celine O'Brien5, Anne Clohessy6, Eamonn Molloy7, Lorraine O Neill8, Fionnuala McAuliffe9 and Douglas Veale10, 1St Vincents Hospital, Dublin, Ireland, 2St Vincent's University Hospital, Dublin, Ireland, 3Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, 4McMaster University, Hamilton, ON, Canada, 5Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, 6National Maternity Hopistal, Dublin, Ireland, 7St Vincent's Healthcare Group, Dublin, Ireland, 8St. Vincent's Hospital, Dublin, Ireland, 9National Maternity Hopsital Dublin, Dublin, Ireland, 10University College Dublin, Dublin, Ireland

    Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
  • Abstract Number: 1709 • ACR Convergence 2021

    Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial

    Min Jung Kim1, Eun Hye Park2 and Kichul Shin3, 1Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, 2Chung-Ang University Hospital, Seoul, Republic of Korea, 3Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term…
  • Abstract Number: 1727 • ACR Convergence 2021

    Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

    Leah Rooney1, Aine Gorman2, Matthew Turk3, Louise Moore4, Celine O'Brien5, Jared Bierbrier6, Anne Clohessy5, Eamonn Molloy7, Lorraine O Neill8, Fionnuala M. Mc Auliffe5 and Douglas Veale9, 1St Vincent's University Hospital, Dublin, Ireland, 2St Vincents Hospital, Dublin, Ireland, 3St. Vincents University Hospital, Dublin, Ireland, 4Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, 5Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, 6McMaster University, Hamilton, ON, Canada, 7St Vincent's Healthcare Group, Dublin, Ireland, 8St. Vincent's Hospital, Dublin, Ireland, 9University College Dublin, Dublin, Ireland

    Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…
  • Abstract Number: 1721 • ACR Convergence 2021

    A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases

    Lauren He, Rachel Karani, Gabriel Arenas and Cuoghi Edens, University of Chicago, Chicago, IL

    Background/Purpose: Reproductive age women with rheumatic diseases are commonly cared for by non-rheumatologists who provide contraceptive counseling, preconception, pregnancy, and post-partum management. When women’s health…
  • Abstract Number: 1724 • ACR Convergence 2021

    More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database

    Anna Molto1, Barbara Roux2, Diep Tran2, Aya Ajrouche2, nathalie costedoat-Chalumeau3, Elisabeth Elefant4, Vassilis Tsatsaris5, Jeanne Fresson6, Brigitte Bader-Meunier7, Bruno Fautrel8 and Florence Tubach2, 1Rheumatology department, Cochin hospital, APHP, Paris, France, 2CEPHEPI, APHP, Paris, France, 3Inserm DR Paris 5, Paris, France, 4Teratogenic agents refernce center (CRAT) , Hôpital Trousseau, APHP, Paris, France, 5Obstetrics Department, Port Royal Maternity, Cochin Hospital, APHP, Paris, France, 6CHU Nancy, Nancy, France, 7Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, 8Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France

    Background/Purpose: Women with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondyloarthritis (SpA)) have been reported to have poorer pregnancy outcomes than the…
  • Abstract Number: 1691 • ACR Convergence 2021

    Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

    Gerd Burmester1, Stanley Cohen2, Kevin Winthrop3, Peter Nash4, Andrea Rubbert-Roth5, Atul Deodhar3, Ori Elkayam6, Eduardo Mysler7, Yoshiya Tanaka8, Jianzhong Liu9, Ana Paula Lacerda9, Bosny Pierre-Louis9, Tim Shaw10 and Philip Mease11, 1Charité University Medicine Berlin, Berlin, Germany, 2Metroplex Clinical Research Center, Dallas, TX, 3Oregon Health & Science University, Portland, OR, 4Griffith University, Brisbane, Australia, 5Kantonspital St Gallen, St.Gallen, Switzerland, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, 8University of Occupational and Environmental Health, Kitakyushu, Japan, 9AbbVie Inc., North Chicago, IL, 10AbbVie Inc., North Chicago, 11Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
  • « Previous Page
  • 1
  • …
  • 544
  • 545
  • 546
  • 547
  • 548
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology